Ocugen Inc (OCGN)

$1.39 0.00 (N/A)
Market Cap 471.36M
Revenue (ttm) 4.41M
Net Income (ttm) -67.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,538.55%
Debt to Equity Ratio -0.11
Volume 2,446,600
Avg Vol 6,719,752
Day's Range N/A - N/A
Shares Out 339.11M
Stochastic %K 47%
Beta 2.21
Analysts Strong Sell
Price Target $10.68

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 328 4701
Address:
11 Great Valley Parkway, Malvern, United States
VINCENZOCOCCOTTI
VINCENZOCOCCOTTI Aug. 24 at 3:21 PM
$OCGN
0 · Reply
Djtrush
Djtrush Aug. 24 at 3:15 PM
$OCGN
0 · Reply
icervantes
icervantes Aug. 24 at 3:08 PM
$OCGN
0 · Reply
Madpatsy
Madpatsy Aug. 24 at 2:40 PM
$OCGN I'll keep this tracker going with how many Sites they open. OCU410ST took ~240 days for 63 patients. *~35,000 Pool of Candidates. *# of sites = 14 OCU410GA take ~___days for 237 patients. *~1,200,000 Pool of Candidates. *3,328.57% increase 33x -> Larger Pool to draw from. *# of sites ___ [3 Currently] Ocugen has opened 32 different sites over their different trials. Used 12 for OCU410 P2. 16 for OCU400. 14 OCU410ST. Very good chance this P3 is recruited quickly or at least for the haters, not delayed. Too many candidates and sites. Ocugen got the clinical process down. THANKS TO HUMA <--- ;)
1 · Reply
Manuelitos
Manuelitos Aug. 24 at 2:38 PM
$OCGN
0 · Reply
SendMeLocation
SendMeLocation Aug. 24 at 2:28 PM
$OCGN lol
0 · Reply
Madpatsy
Madpatsy Aug. 24 at 1:40 PM
$OCGN Potential PRs - PRIOR to 9/21 Vote. According to Me 1. 1st Dose OCU410GA P3 - USA. [Almost a Certainty] ->8/11 Actual Start Date per Clinical Trial Website with 1 active recruiting site McAllen, Texas. ->8/19 Updated added to two more sites, but not yet recruiting. 2. 1st Dose OCU410GA P3 - Europe. ->Shows they are "Global" - Where is the site? Netherlands PM job. 3. OCU410ST Adaptive Design Interim ->Said they won't provide much information, but just need to say, "all good." 4. Definitive Agreement w/ Roots for MENA published. ->anything interesting in there...hmm. 5. OCU200 Phase 1 Data Results -> 24wks timeline from February/March = Early/Mid September 6. Anything on Orthocellix/Neocart -> Bueller...Bueller??? lol
0 · Reply
Jangalang
Jangalang Aug. 24 at 1:38 PM
$OCGN … The nightmare continues every day holding this SCAM.
0 · Reply
Jangalang
Jangalang Aug. 24 at 1:34 PM
$OCGN … Absolute Garbage. 🗑️
0 · Reply
BigMoves1672
BigMoves1672 Aug. 24 at 1:06 PM
$OCGN
0 · Reply
Latest News on OCGN
Ocugen Proxy statement: Proxy filing

Aug 14, 2026, 8:00 AM EDT - 10 days ago

Ocugen Proxy statement: Proxy filing

Ocugen Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 11, 2026, 1:00 PM EDT - 12 days ago

Ocugen Transcript: Canaccord Genuity's 46th Annual Growth Conference

Ocugen Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 18 days ago

Ocugen Earnings Call Transcript: Q2 2026

Ocugen Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 18 days ago

Ocugen Earnings release: Q2 2026

Ocugen Quarterly report: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 18 days ago

Ocugen Quarterly report: Q2 2026

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Aug 6, 2026, 7:02 AM EDT - 18 days ago

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Ocugen to Participate in Upcoming August Investor Conferences

Jul 31, 2026, 7:02 AM EDT - 24 days ago

Ocugen to Participate in Upcoming August Investor Conferences

Ocugen Proxy statement: Proxy filing

Jul 30, 2026, 8:00 AM EDT - 25 days ago

Ocugen Proxy statement: Proxy filing

Ocugen Proxy statement: Proxy filing

Jul 30, 2026, 8:00 AM EDT - 25 days ago

Ocugen Proxy statement: Proxy filing

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Jul 29, 2026, 7:01 AM EDT - 26 days ago

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Jul 28, 2026, 4:01 PM EDT - 26 days ago

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Ocugen Proxy statement: Proxy filing

Jul 20, 2026, 8:00 AM EDT - 5 weeks ago

Ocugen Proxy statement: Proxy filing

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Jul 13, 2026, 7:02 AM EDT - 6 weeks ago

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Ocugen Transcript: Piper Sandler Virtual Ophthalmology Day

Jul 10, 2026, 10:00 AM EDT - 6 weeks ago

Ocugen Transcript: Piper Sandler Virtual Ophthalmology Day

Ocugen to Participate in Upcoming July Industry Conferences

Jul 1, 2026, 7:00 AM EDT - 7 weeks ago

Ocugen to Participate in Upcoming July Industry Conferences

Ocugen Transcript: AGM 2026

Jun 11, 2026, 8:00 AM EDT - 2 months ago

Ocugen Transcript: AGM 2026

Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Jun 4, 2026, 2:30 PM EDT - 2 months ago

Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Jun 2, 2026, 7:03 AM EDT - 2 months ago

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 10:30 AM EDT - 3 months ago

Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

May 14, 2026, 4:30 PM EDT - 3 months ago

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

May 13, 2026, 7:02 AM EDT - 3 months ago

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

Ocugen Provides Business Update with First Quarter 2026 Financial Results

May 5, 2026, 8:32 AM EDT - 3 months ago

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

Ocugen Earnings Call Transcript: Q1 2026

Ocugen Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

Ocugen Earnings release: Q1 2026

Ocugen Quarterly report: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

Ocugen Quarterly report: Q1 2026

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

May 5, 2026, 8:12 AM EDT - 3 months ago

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

May 4, 2026, 4:01 PM EDT - 3 months ago

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Apr 29, 2026, 7:02 AM EDT - 4 months ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Ocugen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Ocugen Proxy statement: Proxy filing

Ocugen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Ocugen Proxy statement: Proxy filing

Ocugen to Present at April 2026 Investor and Industry Conferences

Apr 23, 2026, 7:02 AM EDT - 4 months ago

Ocugen to Present at April 2026 Investor and Industry Conferences

Ocugen Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Ocugen Proxy statement: Proxy filing

Ocugen Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Ocugen Proxy statement: Proxy filing

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Apr 1, 2026, 7:02 AM EDT - 5 months ago

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Ocugen Transcript: Study update

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Ocugen Transcript: Study update

Ocugen Press release: Study update

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Ocugen Press release: Study update

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Mar 24, 2026, 7:45 AM EDT - 5 months ago

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Mar 23, 2026, 7:02 AM EDT - 5 months ago

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Ocugen Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

Ocugen Earnings Call Transcript: Q4 2025

Ocugen Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

Ocugen Annual report: Q4 2025

Ocugen Earnings release: Q4 2025

Mar 4, 2026, 8:30 AM EST - 6 months ago

Ocugen Earnings release: Q4 2025

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 8:15 AM EST - 6 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Mar 2, 2026, 7:02 AM EST - 6 months ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Feb 9, 2026, 7:02 AM EST - 7 months ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 23, 2026, 8:00 AM EST - 7 months ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 7 months ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Ocugen Transcript: Study result

Jan 15, 2026, 8:30 AM EST - 7 months ago

Ocugen Transcript: Study result

Ocugen Press release: Study result

Jan 15, 2026, 8:30 AM EST - 7 months ago

Ocugen Press release: Study result

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 15, 2026, 8:15 AM EST - 7 months ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 13, 2026, 7:00 AM EST - 7 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 12, 2026, 6:30 AM EST - 8 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Jan 9, 2026, 7:02 AM EST - 8 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 10, 2025, 9:20 AM EST - 9 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 20, 2025, 7:02 AM EST - 9 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Ocugen Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Ocugen Earnings Call Transcript: Q3 2025

Ocugen Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Ocugen Quarterly report: Q3 2025

Ocugen Earnings release: Q3 2025

Nov 5, 2025, 8:30 AM EST - 10 months ago

Ocugen Earnings release: Q3 2025

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Nov 5, 2025, 6:30 AM EST - 10 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 10 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Sep 25, 2025, 9:30 AM EDT - 11 months ago

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 15, 2025, 6:03 AM EDT - 1 year ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Sep 2, 2025, 7:02 AM EDT - 1 year ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 13, 2025, 6:27 AM EDT - 1 year ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 12, 2025, 3:45 PM EDT - 1 year ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 1 year ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen Earnings Call Transcript: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q2 2025

Ocugen Quarterly report: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q2 2025

Ocugen Earnings release: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q2 2025

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Aug 1, 2025, 8:25 AM EDT - 1 year ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 21, 2025, 7:30 AM EDT - 1 year ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 18, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jul 17, 2025, 6:30 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 1 year ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 1 year ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q1 2025

Ocugen Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q1 2025

Ocugen Earnings release: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q1 2025

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 1 year ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Ocugen Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings Call Transcript: Q4 2024

Ocugen Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Annual report: Q4 2024

Ocugen Earnings release: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings release: Q4 2024

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

VINCENZOCOCCOTTI
VINCENZOCOCCOTTI Aug. 24 at 3:21 PM
$OCGN
0 · Reply
Djtrush
Djtrush Aug. 24 at 3:15 PM
$OCGN
0 · Reply
icervantes
icervantes Aug. 24 at 3:08 PM
$OCGN
0 · Reply
Madpatsy
Madpatsy Aug. 24 at 2:40 PM
$OCGN I'll keep this tracker going with how many Sites they open. OCU410ST took ~240 days for 63 patients. *~35,000 Pool of Candidates. *# of sites = 14 OCU410GA take ~___days for 237 patients. *~1,200,000 Pool of Candidates. *3,328.57% increase 33x -> Larger Pool to draw from. *# of sites ___ [3 Currently] Ocugen has opened 32 different sites over their different trials. Used 12 for OCU410 P2. 16 for OCU400. 14 OCU410ST. Very good chance this P3 is recruited quickly or at least for the haters, not delayed. Too many candidates and sites. Ocugen got the clinical process down. THANKS TO HUMA <--- ;)
1 · Reply
Manuelitos
Manuelitos Aug. 24 at 2:38 PM
$OCGN
0 · Reply
SendMeLocation
SendMeLocation Aug. 24 at 2:28 PM
$OCGN lol
0 · Reply
Madpatsy
Madpatsy Aug. 24 at 1:40 PM
$OCGN Potential PRs - PRIOR to 9/21 Vote. According to Me 1. 1st Dose OCU410GA P3 - USA. [Almost a Certainty] ->8/11 Actual Start Date per Clinical Trial Website with 1 active recruiting site McAllen, Texas. ->8/19 Updated added to two more sites, but not yet recruiting. 2. 1st Dose OCU410GA P3 - Europe. ->Shows they are "Global" - Where is the site? Netherlands PM job. 3. OCU410ST Adaptive Design Interim ->Said they won't provide much information, but just need to say, "all good." 4. Definitive Agreement w/ Roots for MENA published. ->anything interesting in there...hmm. 5. OCU200 Phase 1 Data Results -> 24wks timeline from February/March = Early/Mid September 6. Anything on Orthocellix/Neocart -> Bueller...Bueller??? lol
0 · Reply
Jangalang
Jangalang Aug. 24 at 1:38 PM
$OCGN … The nightmare continues every day holding this SCAM.
0 · Reply
Jangalang
Jangalang Aug. 24 at 1:34 PM
$OCGN … Absolute Garbage. 🗑️
0 · Reply
BigMoves1672
BigMoves1672 Aug. 24 at 1:06 PM
$OCGN
0 · Reply
WayLoSellHi
WayLoSellHi Aug. 24 at 1:00 PM
$OCGN Let's get the last full week of month 2 of Q3 off in a green way Ocufam 💚
0 · Reply
FullTimeDreamer
FullTimeDreamer Aug. 24 at 12:58 PM
$OCGN
0 · Reply
SendMeLocation
SendMeLocation Aug. 24 at 12:57 PM
$OCGN its been just 5 years of telling me it will be this year
1 · Reply
LittleDerwin
LittleDerwin Aug. 24 at 12:57 PM
$OCGN 🐂
0 · Reply
ChiefNC9
ChiefNC9 Aug. 24 at 12:29 PM
$OCGN let's see some green
0 · Reply
HowULuvThis
HowULuvThis Aug. 24 at 12:20 PM
$OCGN Is it all a dream...👊😎👊
0 · Reply
To_De_Moon
To_De_Moon Aug. 24 at 8:02 AM
$OCGN green monday
0 · Reply
Mr_Stockers
Mr_Stockers Aug. 24 at 7:20 AM
$OCGN
0 · Reply
nickw34q
nickw34q Aug. 24 at 7:13 AM
$OCGN good morning 🌅
0 · Reply
Mart41
Mart41 Aug. 24 at 6:32 AM
$OCGN HUGE UPSIDE🚀
0 · Reply
mickyblue63
mickyblue63 Aug. 24 at 6:22 AM
$OCGN then you need ocugen ,your eyes are fucked, Mega
0 · Reply
Pit1908
Pit1908 Aug. 24 at 6:04 AM
$OCGN REMEMBER..🧬✍🏻💪🏻💚 Ocugen has initiated the Phase 3 trial of OCU410 and plans to submit regulatory filings in 2027. This step follows the approval of the study protocol by the U.S. Food and Drug Administration (FDA). The study, which focuses on the treatment of geographic atrophy, is expected to recruit approximately 237 participants worldwide. Administration of the drug in this pivotal registration trial is expected to begin in September 2026.
0 · Reply